A tensile testing machine exerts tensile force to biological, tissue attached to a bone. A fixture 10 according to the present invention includes a holder 11, which holds a bone B, and a support 12, which supports the holder 11. The holder 11 is provided with around-bone-axis angle adjusting mechanisms 14, 15, which adjust the angle of rotation of the bone B around the bone axis of the hone B held by the holder 11. The holder 11 and the support 12 are provided with bone inclination angle adjusting mechanisms 15, 34, which adjust the inclination angle of the bone B held by the holder 11. The support 12 is provided with lateral position adjusting mechanisms 34, 35, which adjust the lateral position of the holder 11 and longitudinal position adjusting mechanisms 35, 36, which adjust the longitudinal position of the holder 11.

Described are graft devices useful for treating surgical defects, delivery implements for delivery of the graft devices, combinations thereof, and methods for the preparation and use thereof. In certain aspects a tonsillectomy graft can include convexly curved outer edges, where the graft is sized and configured such that these outer edges reside proximate and along tonsillar pillars bounding a surgical tonsillectomy defect. The graft can include one or more pull tethers laced to the graft and functional to draw these outer edges toward one another when tensioned. The graft can be combined with a delivery implement having a delivery head and attached handle, where the delivery head is sized for receipt onto the tonsillectomy defect to deliver the graft. Additional product features, as well as associated methods, are also described.

A polymer film can be adjusted to movement or a fine uneven surface of a living body and has excellent ability to adhere to a biological tissue. The polymer film includes a block copolymer having a structure in which branched polyalkylene glycol and polyhydroxyalkanoic acid are bound to each other, wherein the polymer film has a film thickness of 10 to 1000 nm. The branched polyalkylene glycol has at least three terminal hydroxyl groups per molecule, the mass percentage of the branched polyalkylene glycol relative to the total mass of the block copolymer is 1% to 30%, and a value obtained by dividing the average molecular weight of polyhydroxyalkanoic acid in the block copolymer by X that is the number of terminal hydroxyl groups present per a single molecule of the branched polyalkylene glycol is 10000 to 30000.

The present invention is directed to a process for making a tissue regeneration matrix. The process comprises providing a collagen-tropoelastin dispersion; freeze-drying the dispersion to provide a porous freeze-dried matrix; and then crosslinking the porous freeze-dried matrix. The present invention is also directed to a tissue regeneration matrix prepared by the process.

The present invention is directed to a process for making a tissue regeneration matrix. The process comprises providing a collagen-tropoelastin dispersion; freeze-drying the dispersion to provide a porous freeze-dried matrix; and then crosslinking the porous freeze-dried matrix. The present invention is also directed to a tissue regeneration matrix prepared by the process.

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH.sub.2—SO.sub.3H)COOH or Arg-Gly-NH—CH(CH.sub.2—SO.sub.3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to α.sub.5β.sub.1-Integrin, α.sub.vβ.sub.3-Integrin and α.sub.vβ.sub.5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH.sub.2—SO.sub.3H)COOH or Arg-Gly-NH—CH(CH.sub.2—SO.sub.3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to α.sub.5β.sub.1-Integrin, α.sub.vβ.sub.3-Integrin and α.sub.vβ.sub.5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

To provide an agent for hypodermic injection that has excellent flow characteristics, can be used particularly even in thin injection needles, for example with an internal diameter of 0.20 mm or less, and is unlikely to cause pain during injection and inflammation.

The agent for hypodermic injection includes a hydrogel containing sintered hydroxyapatite particles, wherein the sintered hydroxyapatite particle content is 1 to 60% by mass based on the total mass of the agent, and the average particle diameter of the sintered hydroxyapatite particles is 15 μm or less.

A translucent in-vivo indwelling device with a translucent region including a rare earth doped fluorapatite.

A translucent in-vivo indwelling device with a translucent region including a rare earth doped fluorapatite.